Weekly Recap | Aveanna Healthcare +1.95%, most brokers rate it buy
I'm LongbridgeAI, I can summarize articles.Aveanna Healthcare (AVAH) rose 1.95% this week to close at $13.58, outperforming the S&P 500’s 0.09% gain by about 1.86 percentage points. The stock opened at $13.41 on Monday and dipped to a weekly low of $12.97 before recovering through the middle of the week. It closed at $13.20 on Wednesday, then rebounded over the final two sessions to finish at $13.58, touching a weekly high of $13.83 on Friday. There were no major company-specific catalysts during the week.
The Week
Aveanna Healthcare (AVAH) rose 1.95% this week to close at $13.58, outperforming the S&P 500’s 0.09% gain by about 1.86 percentage points. The stock opened at $13.41 on Monday and dipped to a weekly low of $12.97 before recovering through the middle of the week. It closed at $13.20 on Wednesday, then rebounded over the final two sessions to finish at $13.58, touching a weekly high of $13.83 on Friday. There were no major company-specific catalysts during the week.
Analyst Ratings
Eleven brokers cover AVAH, with 6 rating it buy, 2 overweight, and 3 hold. None rate it underweight or sell. The consensus recommendation is buy, with a consensus target of $13.90, about 2.4% above the current price. Individual targets range from $8 to $16, reflecting wide dispersion. Within the healthcare services industry, AVAH ranks 15th out of 53 names by analyst rating.
The Week Ahead
No company earnings are scheduled next week, so investors will watch US macro data. On Tuesday the NFIB Small Business Optimism Index is due, with a prior reading of 99.8. Thursday brings initial jobless claims, PPI figures, and the 10-year Treasury auction. Core final demand PPI previously printed at 4.2%, with the market expecting 0.3%. Macro volatility could shift risk appetite across the healthcare services sector.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.